Toremifene Citrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100880

CAS#: 89778-27-8 (citrate)

Description: Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

Chemical Structure

Toremifene Citrate
CAS# 89778-27-8 (citrate)

Theoretical Analysis

MedKoo Cat#: 100880
Name: Toremifene Citrate
CAS#: 89778-27-8 (citrate)
Chemical Formula: C32H36ClNO8
Exact Mass:
Molecular Weight: 598.089
Elemental Analysis: C, 64.26; H, 6.07; Cl, 5.93; N, 2.34; O, 21.40

Price and Availability

Size Price Availability Quantity
200.0mg USD 150.0 2 Weeks
500.0mg USD 250.0 2 Weeks
1.0g USD 450.0 2 Weeks
2.0g USD 650.0 2 Weeks
5.0g USD 950.0 2 Weeks
10.0g USD 1650.0 2 Weeks
Bulk inquiry

Related CAS #: 89778-27-8 (citrate)   89778-26-7 (free base)    

Synonym: Fareston; FC 1157a; FC-1157a; NK 622; NSC 613680; Toremifene citrate.

IUPAC/Chemical Name: (Z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate


InChi Code: InChI=1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 598.089 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

  1: Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2010 Mar;13(1):20-7. Epub 2009 Nov 10. Review. PubMed PMID: 19901958.

2: Fitzpatrick JM, Schulman C, Zlotta AR, Schröder FH. Prostate cancer: a serious disease suitable for prevention. BJU Int. 2009 Apr;103(7):864-70. Review. PubMed PMID: 19302133.

3: Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009 Mar;55(3):533-42. Epub 2008 Nov 6. Review. PubMed PMID: 19013008.

4: Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv. 2008 Mar;63(3):163-81. Review. PubMed PMID: 18279543.

5: Sieber PR. Treatment of bicalutamide-induced breast events. Expert Rev Anticancer Ther. 2007 Dec;7(12):1773-9. Review. PubMed PMID: 18062751.

6: Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):247-54. Review. PubMed PMID: 17940447.

7: Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007 Sep;178(3 Pt 2):S9-S13. Epub 2007 Jul 20. Review. PubMed PMID: 17644117.

8: Musa MA, Khan MO, Cooperwood JS. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr Med Chem. 2007;14(11):1249-61. Review. PubMed PMID: 17504144.

9: Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007;24(5):361-79. Review. PubMed PMID: 17503894.

10: Palacios S. The future of the new selective estrogen receptor modulators. Menopause Int. 2007 Mar;13(1):27-34. Review. PubMed PMID: 17448265.

Additional Information

Related CAS#
89778-27-8 (Toremifene Citrate)
89778-26-7 (Toremifene free base)